clinical trial · NCT06944496
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.·phase3·not yet recruiting·n = 616
Gastric CarcinomaDisitamab Vedotin+Tislelizumab+Oxaliplatin+CapecitabineTislelizumab+Oxaliplatin+Capecitabine
brief summary
The purpose of this study is to evaluate the efficacy and safety of \*\*Disitamab Vedotin combined with Tislelizumab and CAPOX versus Tislelizumab combined with CAPOX\*\* as first-line treatment for patients with HER2-low advanced gastric or gastroesophageal junction adenocarcinoma.
started
May 15, 2025
primary completion
May 15, 2028
completion
May 15, 2030
last updated
Apr 25, 2025
official title
A Phase III, Randomized Trial Comparing RC48 Plus Chemotherapy and Tislelizumab With Tislelizumab Plus Chemotherapy as First-line Treatment in Participants With HER2 Low Advanced Gastric or Gastrioesophageal Junction Adenocarcinoma (RC48-C039)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol